Dr. Berilgen is a Board-certified radiation oncologist. He graduated magna cum laude with a bachelor’s degree in physics from Washington University in St. Louis, Missouri. He earned his Doctor of Medicine from Baylor College of Medicine in Houston, where he completed clinical rotations at Houston Methodist Hospital and the University of Texas MD Anderson Cancer Center. In 2003, he was honored with the American Society of Hematology Medical Student Award.
Dr. Berilgen completed residency in radiation oncology at the University of Texas Medical Branch (UTMB) School of Medicine in Galveston, where he also completed the Pinnacle Hands-On Intensity-Modulated Radiation Therapy (IMRT) training course. He served as chief resident in radiation oncology from 2008 to 2009. During residency, he pursued additional elective training at MD Anderson Cancer Center, focusing on malignancies of the breast, gastrointestinal tract, and lung. He completed pediatric radiation oncology training at St. Jude Children’s Research Hospital in Memphis, Tennessee.
Throughout his training, Dr. Berilgen gained extensive experience in intensity-modulated radiation therapy (IMRT), 3D conformal radiation therapy, CT/MRI/PET-based simulation, high-dose-rate (HDR) brachytherapy (MammoSite, prostate and gynecologic), and respiratory gating and 4D planning.
Board certified in radiation oncology by the American Board of Radiology, Dr. Berilgen specializes in image-guided radiotherapy (IGRT), intensity modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and volumetric arc therapy (VMAT).
He previously served as medical director and comprehensive cancer center director at Sadler Clinic. He then served as director of radiation oncology at Millennium Physicians. He is now head of radiation oncology and diagnostic imaging at Woodlands Cancer Institute.
Dr. Berilgen is a member of the American Brachytherapy Society (ABS), the Association Radium Society (ARS), the American Society of Clinical Oncology (ASCO), the American Society of Therapeutic Radiology and Oncology (ASTRO) and the Texas Medical Association (TMA).
As medical director of radiation oncology, Dr. Berilgen provides clinical leadership for AON’s radiation oncology initiatives. In this role, he helps guide the development of clinical protocols, expand patient access to new, evidence-based therapies and support the advancement of radiation oncology across the network.
Outside of work, he enjoys playing tennis, chess, and poker.
Clinical Research Experience:
- RayzeBio: Phase 1b single arm, open-label trial of RYZ101 in combination with carboplatin + etoposide + atezolizumab in subjects with somatostatin receptor expressing (SSTR+) extensive stage small cell lung cancer (ES-SCLC): Radioligand Clinical Trial
- PCCTC-DORA c16-174: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Radiopharmaceutical Alpha-emitter Clinical trial
- Merck: Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC
- Merck: A Multicenter, Double Blind, Randomized, Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants with Unresectable Stage III Non-small Cell Lung Cancer
- AstraZeneca: A Phase III, Randomized, Double-blind, Placebo-controlled, Muticenter Study of Durvalumab in Combination with Epacadostat in Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy
- Bristol-Myers Squibb: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab plus Cisplatin, in Combination with Radiotherapy in Participants with Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN).